The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases - PubMed (original) (raw)
Review
The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases
Alena Opattova et al. Gen Physiol Biophys. 2015 Oct.
Abstract
Impairment of "protein quality control" in neurons is associated with etiopathogenesis of neurodegenerative diseases. The worn-out products of cell metabolism should be safely eliminated via the proteasome, autophago-lysosome and exocytosis. Insufficient activity of these degradation mechanisms within neurons leads to the accumulation of toxic protein oligomers, which represent a starting material for development of neurodegenerative proteinopathy. The spectrum of CNS linked proteinopathies is particularly broad and includes Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia, Pick disease, Frontotemporal dementia, Huntington disease, Amyotrophic lateral sclerosis and many others. Although the primary events in etiopathogenesis of sporadic forms of these diseases are still unknown, it is clear that aging, in connection with decreased activity of ubiquitin proteasome system, is the most significant risk factor. In this review we discuss the pathogenic role and intracellular fate of the candidate molecules associated with onset and progression of AD and PD, the protein tau and α-synuclein in context with the function of ubiquitin proteasome system. We also discuss the possibility whether or not the strategies focused to re-establishment of neuroproteostasis via accelerated clearance of damaged proteins in proteasome could be a promising therapeutic approach for treatment of major neurodegenerative diseases.
Similar articles
- Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
Ciechanover A, Kwon YT. Ciechanover A, et al. Exp Mol Med. 2015 Mar 13;47(3):e147. doi: 10.1038/emm.2014.117. Exp Mol Med. 2015. PMID: 25766616 Free PMC article. Review. - Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM, Fischer DF, Ovaa H, Scheper W. Hol EM, et al. Expert Rev Neurother. 2006 Sep;6(9):1337-47. doi: 10.1586/14737175.6.9.1337. Expert Rev Neurother. 2006. PMID: 17009921 Review. - Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.
Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC. Williams A, et al. Curr Top Dev Biol. 2006;76:89-101. doi: 10.1016/S0070-2153(06)76003-3. Curr Top Dev Biol. 2006. PMID: 17118264 Review. - Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Kumar P, Pradhan K, Karunya R, Ambasta RK, Querfurth HW. Kumar P, et al. J Neurochem. 2012 Feb;120(3):350-70. doi: 10.1111/j.1471-4159.2011.07588.x. Epub 2011 Dec 21. J Neurochem. 2012. PMID: 22098618 Review. - Ubiquilin 2: a component of the ubiquitin-proteasome system with an emerging role in neurodegeneration.
Zhang KY, Yang S, Warraich ST, Blair IP. Zhang KY, et al. Int J Biochem Cell Biol. 2014 May;50:123-6. doi: 10.1016/j.biocel.2014.02.018. Epub 2014 Feb 28. Int J Biochem Cell Biol. 2014. PMID: 24589709 Review.
Cited by
- Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases.
McAlary L, Plotkin SS, Cashman NR. McAlary L, et al. CNS Drugs. 2019 Sep;33(9):883-904. doi: 10.1007/s40263-019-00657-9. CNS Drugs. 2019. PMID: 31414322 Free PMC article. Review. - Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
Behl T, Kumar S, Althafar ZM, Sehgal A, Singh S, Sharma N, Badavath VN, Yadav S, Bhatia S, Al-Harrasi A, Almoshari Y, Almikhlafi MA, Bungau S. Behl T, et al. Mol Neurobiol. 2022 Jul;59(7):4257-4273. doi: 10.1007/s12035-022-02851-1. Epub 2022 May 3. Mol Neurobiol. 2022. PMID: 35505049 Review. - Protein misfolding in neurodegenerative diseases: implications and strategies.
Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, McCampbell A, Leblanc G, Venkateswaran A, Nurmi A, Hodgson R. Sweeney P, et al. Transl Neurodegener. 2017 Mar 13;6:6. doi: 10.1186/s40035-017-0077-5. eCollection 2017. Transl Neurodegener. 2017. PMID: 28293421 Free PMC article. Review. - Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
Njomen E, Tepe JJ. Njomen E, et al. J Med Chem. 2019 Jul 25;62(14):6469-6481. doi: 10.1021/acs.jmedchem.9b00101. Epub 2019 Mar 14. J Med Chem. 2019. PMID: 30839208 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical